We conclude that sunitinib effectively inhibits RET/PTC rearrangement cells but not BRAF mutated cells.     ///    "Immunoblotting revealed effective blocking of MEK/ERK pathway in RET/PTC rearrangement cells, but not in BRAF mutated cells. "    ///    Cell cycle analysis showed G1 arrest in RET/PTC rearrangement cells.     ///    Sunitinib inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not BRAF mutation..     ///    "Cell growth of papillary thyroid cancer cells with RET/PTC rearrangement was effectively inhibited at low doses of sunitinib (IC50=0.658 ?M), whereas that of BRAF mutated cells required higher doses. "    ///    "We investigated the effect of sunitinib on papillary thyroid carcinoma cells harboring RET/PTC rearrangement and BRAF mutation using TPC-1M, SNU-790, and B-cPAP cell lines. "    ///    In vivo orthotopic thyroid cancer mouse model demonstrated statistically significant tumor growth inhibition by sunitinib in RET/PTC rearrangement cancer cells. 